Anti-HGAL / GCSAM / GCET2, clone HGAL/830

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide. Germinal center-associated signaling and motility protein / GCSAM, also called GCET2 and HGAL or hGAL, contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL). Protein function: Involved in the negative regulation of lymphocyte motility. It mediates the migration-inhibitory effects of IL6. Serves as a positive regulator of the RhoA signaling pathway. Enhancement of RhoA activation results in inhibition of lymphocyte and lymphoma cell motility by activation of its downstream effector ROCK. Is a regulator of B-cell receptor signaling, that acts through SYK kinase activation. [The UniProt Consortium]